Loading page
Loading page
Loading substance route
Effects vary widely by individual, dose, and context.
The physical effects of nifoxipam can be broken down into several components which progressively intensify proportional to dosage.
The general head space of nifoxipam is described by many as one of intense sedation and decreased inhibition. It contains a large number of typical depressant cognitive effects.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Described as extremely psychologically addictive with significant abuse potential. Compulsive redosing is a noted effect, and regular use leads to habituation. Rebound anxiety following cessation can drive cycles of continued use and dependence.
Physical dependence develops with regular use over weeks, and withdrawal can be life-threatening. Abrupt discontinuation following extended use may result in hypertension, seizures, and potentially death. Gradual tapering over weeks is essential for safe discontinuation.
Nifoxipam has low toxicity relative to dose when used alone, with mouse studies indicating substantially lower toxicity compared to lormetazepam and flunitrazepam. However, it becomes potentially lethal when combined with other depressants such as alcohol, opioids, or barbiturates due to synergistic respiratory depression.
Respiratory depression occurs at high doses and can be life-threatening in overdose or when combined with other CNS depressants; this effect is dose-dependent and uncommon at typical doses when used alone.
Severe overdose may result in coma and permanent brain injury, primarily as a consequence of prolonged respiratory depression; this is mainly a concern in polydrug combinations or extreme dosing.
Paradoxical psychiatric reactions including aggression, violent behavior, irritability, loss of impulse control, and suicidal behavior occur rarely, with an incidence below 1% in the general population. Risk increases in recreational abusers, individuals with mental disorders, children, and those on high-dose regimens. Delusions may manifest during overdose.
Nifoxipam possesses anticonvulsant properties and does not induce seizures during typical use. Paradoxical seizure increase in epileptic individuals is rare. However, abrupt discontinuation after regular extended use carries significant seizure risk and may be fatal; gradual dose tapering is essential.
Nifoxipam is a nitrobenzodiazepine that was originally identified as a minor metabolite of flunitrazepam (marketed as Rohypnol). While it exists primarily as an analytical reference material in pharmacological research, the compound has since emerged on the online designer drug market. It is…
Controlled as a benzodiazepine under Schedule IV of the Controlled Drugs and Substances Act. All benzodiazepines fall under this scheduling regardless of specific listing.
Classified as a Schedule III controlled substance since 2017. Subject to restrictions on possession, distribution, and manufacturing.
Classified as a controlled drug under national legislation. Possession, production, supply, and importation are prohibited.
Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since July 18, 2019. Production, import with intent to distribute, administration to others, and trading are criminal offenses. Possession is prohibited but carries no criminal penalty.
Specifically named as a controlled substance under Verzeichnis E of Swiss narcotics scheduling. Possession and distribution require authorization.
Controlled under the Psychoactive Substances Act, effective May 26, 2016. Production, supply, and importation are criminal offenses. Personal possession is not criminalized under this act, though intent to supply remains prosecutable.
15 sources cited
